Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0FB4W
|
|||
| Drug Name |
CYAD-101
|
|||
| Drug Type |
CAR T Cell Therapy
|
|||
| Indication | Colorectal cancer [ICD-11: 2B91.Z] | Phase 1 | [1] | |
| Company |
Celyad (formerly named Cardio3 BioSciences)
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | NKG2 D activating NK receptor (KLRK1) | Target Info | CAR-T-Cell-Therapy | [1] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT03692429) alloSHRINK - Standard cHemotherapy Regimen and Immunotherapy With Allogeneic NKG2D-based CYAD-101 Chimeric Antigen Receptor T-cells | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.